We investigated the ability of tocilizumab to block this pathway at the source, and our positive results suggest potential uses of this drug for glioma patients in anti-IL6 therapeutic strategies, such as adjuvant therapy combined with TMZ. Here, IL6 is linked to central nervous system cancer.